EXEL

Exelixis
EXEL

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$11.34B
EV
$9.88B
Shares Outstanding
275.03M
Beta
0.29

Wall Street View

Analyst Rating
OUTPERFORM
Analyst Target Price
$41.32
P/E 2025E
18.55x
P/Revenue 2025E
4.87x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Exelixis, Inc.

gainify
EXEL

Exelixis, Inc.

EXEL

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinom...

Sector

Healthcare

Industry

Biotechnology

CEO

Morrissey, Michael

Employees

1,147

IPO Date

2000-04-17

Headquarters

1851 Harbor Bay Parkway, Alameda, California, 94502, United States

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on Trustpilot
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.